24d909f2-cdc8-4509-91d5-e18fffcf90eb
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 62
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.590
- INFLAMMATORY_RESPONSE+0.550
- TNFA_SIGNALING_VIA_NFKB+0.550
- CHOLESTEROL_HOMEOSTASIS+0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
- ALLOGRAFT_REJECTION+0.460
- INTERFERON_GAMMA_RESPONSE+0.460
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.450
- HYPOXIA+0.440
- COMPLEMENT+0.420
Top 10 suppressed
- MYC_TARGETS_V1-0.400
- WNT_BETA_CATENIN_SIGNALING-0.280
- MYC_TARGETS_V2-0.270
- UNFOLDED_PROTEIN_RESPONSE-0.270
- E2F_TARGETS-0.250
- G2M_CHECKPOINT-0.190
- DNA_REPAIR-0.140
- SPERMATOGENESIS-0.020
- PROTEIN_SECRETION-0.010
- PEROXISOME+0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_M4TTKPNR | pilocytic astrocytoma | — | 0.925 |
| 2 | BS_1TPWFSK6 | subependymal giant cell astrocytoma(SEGA) | — | 0.924 |
| 3 | BS_HC5M8JTC | low-grade glioma | — | 0.916 |
| 4 | s0122206 | — | — | 0.914 |
| 5 | SRR663693 | GTEX | — | 0.912 |
| 6 | SRR5088929 | — | — | 0.908 |
| 7 | cc158c27-a2f0-4403-ae01-913bfcc623cc | — | — | 0.905 |
| 8 | C3L-02601 | — | cohortA1 | 0.904 |
| 9 | BS_769BDPDB | pilocytic astrocytoma | — | 0.903 |
| 10 | ERR2208908 | — | — | 0.902 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.590 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.550 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.550 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.500 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.470 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.460 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.460 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.450 | Inavolisib | — uncovered |
| HYPOXIA | 0.440 | Idelalisib | — uncovered |
| COMPLEMENT | 0.420 | Inavolisib | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.370 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.360 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.290 | Inavolisib | — uncovered |
| APOPTOSIS | 0.280 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.270 | Inavolisib | — uncovered |